Unveiling the Role of Irisin as a Biomarker in Adolescent and Young Adult PCOS: A Metabolic and Hormonal Comparison of Hyperandrogenic and Normoandrogenic Phenotypes.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
AIM: Polycystic ovary syndrome (PCOS) in adolescents and young adults is difficult to diagnose due to overlap with normal puberty. This study assessed irisin as a biomarker, comparing metabolic and hormonal profiles of hyperandrogenic (HA) and normoandrogenic (NA) phenotypes, determining an optimal cut-off, examining correlations with clinical markers, and identifying predictors of irisin levels. METHODS: A cross-sectional study was conducted involving 120 females aged 13-21 years, comprising 60 PCOS patients (38 HA-PCOS, 22 NA-PCOS) and 60 healthy controls. Metabolic and hormonal profiles, including serum irisin, insulin resistance indices, lipid profile, and reproductive hormones were assessed. Data were analyzed using SPSS version 22. RESULTS: Irisin levels were significantly elevated in HA-PCOS compared to NA-PCOS (p = 0.004) and controls (p < 0.001). Irisin showed positive correlation with BMI, glucose, insulin, HOMA-IR, TAGs, low-density lipoprotein, and luteinizing hormone, and negative correlation with high-density lipoprotein and QUICKI. An irisin threshold of 18.24 ng/mL demonstrated potential in identifying HA-PCOS (area under curve = 0.802). Multivariate regression identified glucose, TAGs, LH, and HOMA-IR as significant predictors of irisin levels (adjusted R2 = 0.908). CONCLUSION: HA-PCOS is marked by more severe metabolic disruption. Irisin may serve as a promising early biomarker for this phenotype and help predict long-term complications linked to metabolic disruption in PCOS.